Last reviewed · How we verify
BIIB014
BIIB014 is a monoclonal antibody targeting CD20.
BIIB014 is a monoclonal antibody targeting CD20. Used for Relapsed or refractory non-Hodgkin's lymphoma.
At a glance
| Generic name | BIIB014 |
|---|---|
| Sponsor | Biogen |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to CD20 on the surface of B cells, leading to their depletion and subsequent reduction in disease activity.
Approved indications
- Relapsed or refractory non-Hodgkin's lymphoma
Common side effects
- Infusion-related reactions
- Neutropenia
- Anemia
Key clinical trials
- BIIB014 Phase 2a Monotherapy (PHASE2)
- BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam (PHASE1)
- BIIB014 Cardiovascular Monitoring Study (PHASE1)
- Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease (PHASE2)
- Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease (PHASE2)
- Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |